Wednesday, 21 December 2022
Friday, 16 December 2022
Investor Ideas #Potcasts 641, #Cannabis News and #Stocks on the Move- (CSE: $CURA.C) (OTCQX: $CURLF), (Nasdaq: $HITI) (TSXV: $HITI.V)
Investor Ideas #Potcasts 641, #Cannabis News and #Stocks on the Move- (CSE: $CURA.C) (OTCQX: $CURLF), (Nasdaq: $HITI) (TSXV: $HITI.V)
Delta, Kelowna, BC, December 16, 2022
(Investorideas.com Newswire), investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site
release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2022/121622-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2022/cannabis-potcasts/12161CURA-HITI.asp
Hear Investor ideas
cannabis potcast on iTunes
Hear the investor
ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast we look at a few
public company announcements, changes to Canadian Cannabis Act as well some
recent cannabis related news.
Last week, Health Canada announced that amendments to the Cannabis Act
and its regulations concerning cannabis research and testing, and cannabis
beverages have been approved and are now in force as of December 2, 2022. A
copy of the final regulations, as well as the Regulatory Impact and Analysis
Statement is expected to be published in the Canada Gazette, Part II, on December
21, 2022.
These amendments follow extensive
engagement with stakeholders, universities, researchers, health authorities,
cannabis industry associations, cannabis licence holders, provinces,
territories and the public. They aim to facilitate research and testing, and
also amend the public possession limit for cannabis beverages to bring them in
line with other cannabis products.
Notably, these amendments:
●
Increase the public
possession limit for cannabis beverages to a level that is similar to other
forms of cannabis, such as solid edible cannabis products (i.e. gummies or
chocolate). Adults in Canada are now able to possess up to 17.1 litres (equal
to 48 cans of 355 ml each) of cannabis beverages in public for non-medical
purposes, which is up from approximately 2.1 litres (equal to five cans of 355
ml each) under the previous rules. Existing controls that mitigate the risks of
overconsumption and accidental consumption, such as child-resistant packaging
and strict limits on the amount of THC per container, remain in place;
●
Change how Health Canada
regulates non-therapeutic cannabis research with human participants, helping
make the process of conducting this research easier, while still maintaining
appropriate public health and safety controls;
●
Allow analytical testing
licence holders and federal and provincial government laboratories to produce,
distribute and sell reference standards and test kits, to increase access to
cannabis testing materials and thereby support access to a quality-controlled
supply of cannabis; and
●
Broaden the educational
qualifications for the Head of Laboratory, a position that is required for an
analytical testing licence and is responsible for all cannabis testing
activities that occur at the licensed site.
Transition periods are provided to reduce
potential impacts on existing research licence holders conducting research with
human participants, and on processing licence holders who produce cannabis
beverages. The Cannabis Act serves as a flexible legislative framework that
adapts and responds to the needs of Canadians.
Health Canada will continue to engage with
stakeholders and pursue initiatives to address ongoing and emerging public
health and safety issues to improve the cannabis framework so that it meets the
needs of Canadians while continuing to displace the illicit market.
Quick Facts
●
The Cannabis Act (the Act)
came into force on October 17, 2018. With the Act, the Government of Canada
legalized and strictly regulated the production, distribution, sale, import and
export, and possession of cannabis.
●
The Minister of Health and
the Minister of Mental Health and Addictions launched the legislative review of
the Cannabis Act on September 22, 2022. The review is being conducted by a
five-member independent, expert panel, who will report their final conclusions
and advice to the Ministers by Spring 2024.
●
Health Canada's Forward Regulatory Plan provides information
on regulatory initiatives that Health Canada aims to propose or finalise in the
next two years, including those pertaining to the cannabis framework.
Associated Links for More Information:
●
Backgrounder: Amendments on cannabis research and
testing, and cannabis beverages
●
Canada Gazette Part I - Notice of intent
●
Cannabis Exemption (Food and Drugs Act) Regulations
Curaleaf
Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading international
provider of consumer cannabis products, announced that its third "The Farmer's
Select" product collaboration is now available across California in
partnership with Autumn Brands, a woman-and-family-owned farm
nestled on the coast of Santa Barbara County.
Autumn Brands cannabis is grown using
sustainable farming techniques, natural sunlight and 100% no-spray cultivation.
Utilising a closed-loop watering system, Autumn Brands ensures that no water is
wasted during the growing process and all organic waste is composted. This
focus on quality, consistency and sustainability ensures nothing but the best
cannabis reaches consumers.
Select's latest collaboration transforms
Autumn Brands' top-quality, limited-batch cannabis flower into the same Select
Elite Live Oil that customers know and love. The limited-edition product line
is now available at dispensaries across California in three strains including
Jetlato (sativa), Pineapple MAC (hybrid) and Banana Jelly (indica).
"We are proud to align ourselves with
a conscientious, high-quality cultivator like Autumn Brands that prioritises
not just the consumer and the community but also the environment," said
Matt Darin, CEO of Curaleaf. "With each Farmer's Select partnership, we
aim to highlight the skills of innovative growers, talented extractors and
craft operators that are vital to the success of the California cannabis
industry. This program is another example of how operators both large and small
can work together to creative a quality product and an inclusive, diverse
industry."
"California has fostered a rich
cannabis marketplace, and we believe that industry leaders should recognize the
people, brands and businesses that make it all happen. We are thrilled to be a
part of The Farmer's Select Program and support Curaleaf's efforts to uplift
smaller, licensed operators across the state," said Autumn Shelton, CFO
and Co-Founder of Autumn Brands.
Formally launched in July 2022, The
Farmer's Select program is an ongoing series of limited-edition collaborations
with craft farmers and diverse operators in California. The program reflects
Curaleaf's commitment to providing premium products to consumers while
uplifting smaller operators across the Golden State. Select previously
partnered with Sonoma Hills Farm in April 2022 and Delighted Farms in July 2022
– both limited-edition product lines sold out in less than two weeks.
The Select Elite Live Autumn Brands
collaboration is now available at dispensaries across California while supplies
last. For more information on product availability, visit www.selectbetter.com/find-us or visit one of
the participating retailers below.
Merrco
Payments Inc., a leader in cannabis payments, and Gratify Payments Inc., the BNPL
platform for payment companies, announced the launch of buy now pay later for
Ontario cannabis retailers - a Canadian first. Gratify is a buy now pay later
platform that offers a new way for retailers to meet consumer demand through
payment plans. BNPL from Gratify helps cannabis retailers sell accessories and
other high-ticket items, and helps consumers use the payment method that best
suits them.
"Buy now pay later has been an exciting
addition to how Canadians want to pay," said Fern Glowinsky, Merrco
President and CEO. "Today, we're pioneering cannabis payments yet again
and supporting cannabis retailers with new payment options just in time for the
holiday season."
Features and benefits of Buy Now Pay Later
from Gratify include:
●
Help cannabis retailers
offer more payment options to their customers
●
Match the same range of
payment experiences available in retail
●
Keep up with consumer
demand for payment method choice at the check out
"The cannabis retail industry is
maturing, and consumers expect the same payment
experience they get elsewhere," says
Ryan Brough, CEO of Gratify. "We're proud to help cannabis retailers in
Ontario be first in Canada to accept buy now pay later."
Gratify BNPL will be available starting
Dec. 12, 2022, for cannabis retailers served by Merrco in Ontario. For more
information, visit www.merrco.com/bnpl.
High
Tide Inc. (Nasdaq: HITI) (TSXV: HITI), a leading retail-focused cannabis
company with bricks-and-mortar as well as global e-commerce assets, announced that it has begun selling cannabis
seeds in the United States, initially through its wholly owned subsidiaries Grasscity and Smoke Cartel, which are the two most popular
e-commerce platforms for consumption accessories in the world.2 The Company
plans to expand seed sales to additional online retail platforms within its
portfolio in 2023.3 This launch comes on the heels of the American Drug
Enforcement Agency's recent official determination that cannabis seeds fall
under the legal definition of hemp and can therefore be sold openly in the
United States.
"With our entry into this new and
exciting complementary vertical, we continue to extend and strengthen our
integrated value chain, providing our customers with a complete cannabis
experience, in addition to the opportunity to further enhance our consolidated
gross margin profile. This new business venture will greatly expand our U.S.
customer base, which already sits at 2.4 million through our ancillary cannabis
business lines, and sets us up well to take advantage of federal legalization
in the United States when it comes. This further diversification into the U.S.
seeds market also strengthens our Canadian discount club model, as this new
vertical is expected to generate significantly higher gross margins than our
core brick-and mortar-business, which will help us continue to offer unbeatable
prices to our Cabana Club members," said Raj Grover, President and Chief
Executive Officer of High Tide.
"GrassCity and Smoke Cartel, due to
their top SEO rankings, organically built over the last twenty-two and eight
years, respectively, generate some of the highest online traffic in the
consumption accessories space, which is why it makes sense for us to leverage
this strength as we launch this new vertical in the United States. Innovation
has always been a cornerstone of High Tide's strategy, and today's announcement
is yet another example of how we will never stop looking for ways to enhance
shareholder value while differentiating ourselves from the competition,"
added Mr. Grover.
Lastly today, a quick look at two recent news
pieces related to the cannabis industry.
One from the Washington Post, comparing the risks
associated with alcohol and cannabis, and another from the BBC, on a man committing manslaughter due to
“cannabis-induced psychosis”.
I point to both of these to highlight the
current rhetoric surrounding high-THC cannabis and the many supposed “unknown
risks” involved with it, as well as how both the media and the medical
community in general continue to perceive and view cannabis.
Both articles skew heavily towards the
“dangers” of cannabis and seem to overplay the influence cannabis has on
individuals as well as both demonstrate the use of specific word usage to
suggest a greater danger than is factually proven.
When looking at the cannabis industry, one
cannot disregard these top trending news pieces as one offs or as obvious scare
propaganda as the impact they have on the masses as well as legislators is very
real and very damaging to the success of the industry as a whole.
Often these singular cases are used as
evidence against the industry when the conversation comes to decriminalisation
or rescheduling and I have often discussed the one-sided nature of the cannabis
discussion when it comes to research and medical evidence. The lack of credit
given to independent researchers, often those who are not federally funded,
combined with an overselling of the “dangers” and “risks” of high-THC product
from mainstream news organisations can be viewed as the biggest indicators of
where the industry currently is and where it is heading in the near future.
Many who have supported this industry since
the grass-roots days have voiced their disappointment on the direction the
industry has taken in the last few years with Canadian federal legalisation as
well as individual state legalisation.
While I think most of us hope to see this
industry follow in the footsteps of craft beer and boutique wineries, what we
are seeing is a growing push to have this industry completely handed over to
mega-pharma corporations. If that does happen most of the safety and natural
medical benefits this industry has provided so far may fall into the same
category of prescription medications soon enough.
When looking at continuing to invest in
cannabis, we should all be considering not only what looks to be the short term
and long term winners within the space, but also where we all want the space to
go as it evolves. If cannabis becomes just another pharma product will the
fight for legalisation and medical access be lost? Will that mean that in the
end, government and corporate propaganda couldn’t be beaten?
Investorideas has tried many times to
promote the idea of investing not only in your financial future, but also the
future of ideas. When considering your next cannabis investment, please
consider the future of cannabis as a whole and what the industry is meant to
represent, not just as a short or long term money maker, otherwise it makes
much more sense to invest in gold, silver and oil.
Investor ideas reminds all listeners to
read our disclaimers and disclosures on the Investorideas.com website and that
this podcast is not an endorsement to buy products or services or securities.
Investors are reminded all investment involves risk and possible loss of
investment.
About
Investorideas.com - Big Investing Ideas
We publish breaking
stock news, stock research, guest posts and create original top rated investing
podcasts, plus sector tag articles featuring up and coming companies and
industry leaders. Investor Idea’s
original branded content includes the Crypto
Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock
directories for AI and tech, biotech, cannabis, cleantech, crypto, defense,
gaming, health and wellness, mining, oil and gas, sports and water.
The Investorideas.com podcasts are also available on Apple Podcasts
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio, Google Podcasts
and most audio platforms available.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing
your news release and our other news services on the Investorideas.com
newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except
where permissible by law. Our site does not possess, distribute, or sell
cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Wednesday, 14 December 2022
Tuesday, 13 December 2022
Friday, 9 December 2022
Investor Ideas #Potcasts 640, #Cannabis News and #Stocks on the Move- Cannabis legislation in the US, cannabis retail sales in Canada and the US
Investor Ideas #Potcasts 640, #Cannabis News and #Stocks on the Move- Cannabis legislation in the US, cannabis retail sales in Canada and the US
Delta, Kelowna, BC, December 9, 2022
(Investorideas.com Newswire), investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site
release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2022/120922-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2022/cannabis-potcasts/12091Legislation-Retail-Sales-Canada-US.asp
Hear Investor ideas
cannabis potcast on iTunes
Hear the investor
ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast we look at some of the
recent news regarding cannabis legislation in the US, cannabis retail sales in
Canada and the US and how these developments have impacted the markets.
This week’s major cannabis news saw shares of many
cannabis multi-state operators (MSOs) tumbling down on reports that legislation
that would legalise banking services for marijuana companies in the US is now
unlikely to pass the Senate by the end of the year.
Attempts to include a version of the Secure
and Fair Enforcement (SAFE) Banking Act, which would prevent federal banking
regulators from imposing penalties on banks and other financial institutions
for providing services to legal cannabis businesses, in the must-pass annual
National Defense Authorization Act (NDAA) were opposed by Republican leaders.
Democrats had pushed for the inclusion of
cannabis banking language in the NDAA, however, the NDAA was released on
Tuesday without any references to cannabis, crushing any hope that legislation
for legalising marijuana banking would pass by year-end.
A version of the NDAA with the language of
the SAFE Banking Act included was approved by the House earlier this year. This
is a story that has played out in the House and Senate several times over the
past few years as many investors and cannabis operators are well aware of.
The SAFE Banking Act as a standalone piece
of legislation has attracted broad bipartisan support to date and it is
understood Republicans opposed the use of the NDAA as a vehicle for this
reform.
The market reacted negatively to the news,
with the AdvisorShares Pure US Cannabis ETF down 8% and the AdvisorShares Pure
Cannabis ETF falling 4.5% at mid-morning on Wednesday.
This was a change from the stock rally we
saw early Monday following last week’s news of President Joe Biden making
history on Friday when he became the first American president to sign marijuana-specific reform legislation into law.
Biden affixed his signature to the
bipartisan Medical Marijuana and Cannabidiol Research Expansion Act, the White
House announced.
The landmark legislation, which is intended
to make it easier for scientific researchers to study the plant, also calls on
the federal government to look into the potential therapeutic benefits of
marijuana and could thus help steer the ongoing rescheduling review Biden launched in
October.
Co-sponsors of the bill include Sens. Chuck
Grassley, R-Iowa, and Dianne Feinstein, D-California, as well as key members of
the House who support marijuana reform, including U.S. Rep. Earl Blumenauer,
D-Oregon, Nancy Mace, R-South Carolina, and Dave Joyce, R-Ohio.
The first marijuana reform bill to be passed by both chambers of Congress after it
cleared the Senate last month via a process called unanimous consent, the bill
allows research universities – including those that receive federal funding,
which, to date, have been wary of dealing with the federally illegal drug – as
well as private companies to acquire U.S. Drug Enforcement Administration
licences to grow and handle cannabis for research purposes.
There are currently only seven institutions with DEA permits to
grow cannabis for research.
The bill also directly instructs the
federal Department of Health and Human Services (DHHS) to research “the
therapeutic potential of marijuana,” though it also requires the agency to
study how cannabis might impair the development of adolescent brains as well as
the ability to operate a motor vehicle.
Something to consider is as more federal
organisations and Universities are able to access cannabis for research
purposes, we could see the research quality deteriorate as one recent Harvard Study shows.
This recent study implies that cannabis is
as effective as the placebo effect, though upon further reading we can see that
the study actually drew no real conclusions in the end.
The active treatments used in these studies
included two main cannabinoids in marijuana, delta-9-tetrahydrocannabinol (THC)
or cannabidiol (CBD), and the prescription drugs nabilone (Cesamet), dronabinol
(Marinol, Syndros), and nabiximols (Sativex). The products — and the placebos —
were given as a pill, spray, oil, or smoke or vapour. The researchers found
that participants receiving active treatment and participants receiving placebo
reported similar levels of pain relief.
Ted J. Kaptchuk, director of the Program in
Placebo Studies and The Therapeutic Encounter at Harvard-affiliated Beth Israel
Deaconess Medical Center, says the findings from this well-done study aren’t
surprising. "With the exception of opioids, most pain-relieving
medications are barely better than a placebo," he says.
In fact, in clinical trials of common pain
medications such as aspirin and ibuprofen, placebos provide about as much pain
relief as the actual drugs. That’s not to say active medications don’t have
physiological effects. Rather, the effects of a placebo rival or mimic those
effects. They just work through different neurobiological pathways, Kaptchuk
explains.
While allowing Universities more access to
cannabis research may seem a benefit to the cannabis industry on the face of
it, we have seen over recent years the quality of many University studies
deteriorate due to a variety of factors such as the involvement of political
ideologies, corporate sponsorship and a general trend of conformity amongst
University students and faculty.
Another factor of Biden’s cannabis research
bill is this specific wording which “requires the agency to study how cannabis
might impair the development of adolescent brains as well as the ability to
operate a motor vehicle.”
This has been another element we have seen
blown out of proportion often in mainstream media and from federal
organisations in Canada and is often used as an excuse to limit the access of
cannabis to strictly pharma based companies, supposedly the only companies
deemed “safe” for handling such “potentially dangerous substances”. This can
also be used against recreational access even though certain research does
point to cannabis use actually being the safe choice over alcohol, a federally
legal substance across the globe, in that cannabis users often avoid driving
while impaired, unlike alcohol users who feel emboldened to drive, and that
cannabis users often choose safe ride alternatives far more often than alcohol
users.
There is also the discussion of safety for
children, even though this bypasses the discussion of cannabis as an effective
medicine for many children suffering from autism and epilepsy or the recent
research connected to antidepressants, a drug often prescribed to youths, which
has been shown to have drastic negative side effects, unlike cannabis which as
of yet has not been linked to any developmental issues amongst youths.
In recent Canadian news, Canadian cannabis
producers and brands increasingly are, in effect, paying Ontario retailers for
shelf space and other special treatment for their products, according to
industry executives.
This is also the case in almost all other
provinces in Canada.
Many executives allege the effective use of
so-called slotting fees threatens the survival of hundreds of independently
owned retailers and craft cultivators, who lack the money and resources to
finance such pay-to-play schemes.
The monthly fee can amount to tens of
thousands of dollars or more, according to one industry source who declined to
be identified for competitive reasons.
Slotting fees, common for decades in
traditional retail, are a relatively new phenomenon in cannabis in both the United States and Canada.
In Ontario, regulators prohibit producers
and brands from paying retailers for favourable “material” treatment.
What no-one seems to be addressing is that
this is largely due to the strict laws surrounding the cannabis industry when
it comes to branding, advertising and marketing. Many within the industry are
well aware of this reality and see this is their only competitive access point
when dealing with the retail market.
Lastly, Connecticut’s first legal cannabis
shops will open next month.
The Department of Consumer Protection
announced Friday morning that it has notified some of the existing medical
marijuana dispensaries in the state that they can begin selling recreational
pot to all adults 21 and over as soon as 10 a.m. on Jan. 10.
“We know that many people are excited to
participate in this marketplace, whether as a business or a consumer, and we
encourage adults who choose to purchase and consume these products to do so
responsibly once sales begin on January 10,” DCP Commissioner Michelle H.
Seagull said in a written statement.
Customers will be able to buy up to a
quarter ounce of cannabis at a time. DCP said purchase limits will continue to
be reviewed over time and help maintain adequate supply for both adult-use
consumers and medical marijuana patients, who can purchase up to five ounces of
cannabis per month.
DCP is advising medical patients to
purchase any necessary medication before Jan. 10, or at one of the nine
medical-only dispensaries in the state, as long lines and traffic are expected
during the opening weeks of adult-use sales.
Connecticut’s recreational market is
launching four years after Massachusetts became the first state on the East
Coast to open legal pot stores. Recreational sales began in New Jersey in April
and New York is on the precipice of launching its legal market. Rhode Island
gave the green light to its existing medical marijuana dispensaries to sell
recreational pot starting Dec. 1.
While this is a benefit for the state and
will allow greater access for more consumers, note that yet again, the medical
industry takes a backseat to recreational sales.
About
Investorideas.com - Big Investing Ideas
We publish breaking
stock news, stock research, guest posts and create original top rated investing
podcasts, plus sector tag articles featuring up and coming companies and
industry leaders. Investor Idea’s
original branded content includes the Crypto
Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock
directories for AI and tech, biotech, cannabis, cleantech, crypto, defense,
gaming, health and wellness, mining, oil and gas, sports and water.
The Investorideas.com podcasts are also available on Apple Podcasts
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio, Google Podcasts
and most audio platforms available.
Visit the Podcast page at
Investorideas.com: https://www.investorideas.com/Audio/
Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. This site is currently compensated
for news publication and distribution, social media and marketing, content
creation and more. Disclosure is posted for each compensated news release,
content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/
Investor Ideas does not condone the use of cannabis except
where permissible by law. Our site does not possess, distribute, or sell
cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...